<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735473</url>
  </required_header>
  <id_info>
    <org_study_id>PSYCH-2016-23989</org_study_id>
    <secondary_id>R01AA024123</secondary_id>
    <nct_id>NCT02735473</nct_id>
  </id_info>
  <brief_title>Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders</brief_title>
  <official_title>Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial of choline supplementation in&#xD;
      children with Fetal Alcohol Spectrum Disorders (FASD). The primary outcome measures are&#xD;
      cognitive measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is the third in a series of randomized, double-blind placebo-controlled trials&#xD;
      of choline bitartrate in children ages 2-5 who have been diagnosed with Fetal Alcohol&#xD;
      Spectrum Disorders (FASD). Pre-clinical data suggests that choline may attenuate the&#xD;
      cognitive deficits caused by prenatal alcohol exposure (especially memory deficits). This&#xD;
      study will evaluate the effects of daily choline supplementation vs. placebo for 9 months.&#xD;
      Outcome measures include an elicited imitation memory paradigm, global cognitive functioning,&#xD;
      and aspects of executive functioning. The study will also continue to collect safety and&#xD;
      tolerability data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">September 10, 2021</completion_date>
  <primary_completion_date type="Actual">September 10, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elicited Imitation memory task - Short delay memory measure: 6 months</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Elicited Imitation memory paradigm - short delay memory measure at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elicited Imitation memory task - Short delay memory measure: 9 months</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Elicited Imitation memory paradigm - short delay memory measure at 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stanford-Binet Intelligence Scales: 9 months</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Stanford-Binet Intelligence Scales at 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Executive Function Scale: 6 months</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Minnesota Executive Function Scale - Early Childhood Version at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Executive Function Scale: 9 months</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Minnesota Executive Function Scale - Early Childhood Version at 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Toolbox Flanker Task: 6 months</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>NIH Toolbox Flanker Inhibitory and Control Task at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Toolbox Flanker Task: 9 months</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>NIH Toolbox Flanker Inhibitory and Control Task at 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Behavior Checklist: 6 months</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Child Behavior Checklist - parent report instrument at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Behavior Checklist: 9 months</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Child Behavior Checklist - parent report instrument at 9 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Fetal Alcohol Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Choline bitartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powdered drink mix containing choline bitartrate 19 mg. per kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Powdered drink mix containing matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choline bitartrate</intervention_name>
    <arm_group_label>Choline bitartrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 2 years to 5 years of age&#xD;
&#xD;
          2. Available parent or legal guardian capable of giving informed consent for&#xD;
             participation.&#xD;
&#xD;
          3. Documented prenatal alcohol exposure (self-report, social service records, or adoption&#xD;
             records).&#xD;
&#xD;
          4. Modified Institute of Medicine (IOM) criteria for Fetal Alcohol Syndrome (FAS),&#xD;
             Partial Fetal Alcohol Syndrome (PFAS), or Alcohol-Related Neurodevelopmental Disorder&#xD;
             (ARND) (Hoyme, May, et al., 2005).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of a neurological condition (ex. epilepsy, traumatic brain injury)&#xD;
&#xD;
          2. Known history of a medical condition known to affect brain function.&#xD;
&#xD;
          3. Known history of other neurodevelopmental disorder (ex. autism, Down syndrome)&#xD;
&#xD;
          4. Known history of very low birthweight (&lt;1500 grams)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey R Wozniak, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 2, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Alcohol Spectrum Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02735473/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

